Table 5.
Trends in cannabis use disorder severity (meeting at least any two or more of the nine DSM-5 criteria (legal problems removed)) and the number of endorsed DSM-5 criteria among adults (N=749,5001) and among adults with past-year cannabis use (N=145,5001)
| Meeting DSM-5 criteria for a cannabis use disorder | 12-month prevalence, weighted percentage (95% confidence interval) | Examined all 16 years of data during 2002–2017: β coefficents, p values for the overall trends | |
|---|---|---|---|
| 2002 | 2017 | ||
| Any 2+ criteria of nine DSM-5 criteria in adults | 2.1 (1.93–2.25) | 2.6 + (2.42–2.73) | β= 0.0155; p<0.0001** |
| Any 2–3 criteria of the nine DSM-5 criteria in adults | 1.4 (1.26–1.52) | 1.9 + (1.78–2.04) | β= 0.0251; p<0.0001** |
| Any 4–5 criteria of the nine DSM-5 criteria in adults | 0.5 (0.38–0.53) | 0.5 (0.41–0.54) | β= −0.0053; p=0.1966 |
| Any 6+ criteria of the nine DSM-5 criteria in adults | 0.3 (0.21–0.31) | 0.2 (0.16–0.24) | β= −0.0175; p=0.0019** |
| Any 2+ criteria of the nine DSM-5 criteria in adult users | 20.1 (18.76–21.45) | 16.8+ (15.89–17.72) | β= −0.0169; p<0.0001** |
| Any 2–3 criteria of the nine DSM-5 criteria in adult users | 13.3 (12.22–14.49) | 12.4 (11.65–13.28) | β= −0.0050; p=0.0342 |
| Any 4–5 criteria of the nine DSM-5 criteria in adult users | 4.3 (3.69–5.03) | 3.1+ (2.68–3.53) | β= −0.0343; p<0.0001** |
| Any 6+ criteria of the nine DSM-5 criteria in adult users | 2.4 (2.00–2.97) | 1.3 + (1.04–1.54) | β= −0.0455; p<0.0001** |
| Any 2+ criteria of the nine DSM-5 criteria in adult daily/near daily users | 48.7 (44.5–52.91) | 36.8 + (34.39–39.30) | β= −0.0425; p<0.0001** |
| any 2–3 criteria of the nine DSM-5 criteria in adult daily/near daily users | 31.7 (28.36–35.26) | 27.3 + (25.11–29.61) | β= −0.0191; p<0.0001** |
| any 4–5 criteria of the nine DSM-5 criteria in adult daily/near daily users | 10.4 (8.30–13.06) | 6.8 + (5.60–8.16) | β= −0.0451; p<0.0001** |
| any 6+ criteria of the nine DSM-5 criteria in daily/near daily users | 6.5 (5.20–8.20) | 2.7 + (2.12–3.53) | β= −0.0637; p<0.0001** |
| Mean number of symptoms meeting DSM-5 (nine) criteria | Weighted mean number of endorsed criteria (95% confidence interval) | Examined all 16 years of data during 2002–2017: β coefficents, p values for the overall trends | |
| 2002 | 2017 | ||
| Adults | 0.09 (0.081–0.093) | 0.10+ (0.096–0.108) | β= 0.0011; p<0.0001** |
| Adult users | 0.83 (0.784–0.883) | 0.66+ (0.634–0.698) | β= −0.0130; p<0.0001** |
Notes:
Data source: Substance Abuse and Mental Health Services Administration’s the 2002–2017 National Surveys on Drug Use and Health (NSDUH) data. Weighted prevalence estimates are reported. SAMHSA requires that any description of overall sample sizes based on the restricted-use NSDUH data files be rounded to the nearest 100 to minimize potential disclosure risk. +Difference between the estimate in which the footnote symbol appears and the 2002 estimate (the reference year) is statistically significant at the .05 level. Bivariable logistic regression models were applied for testing differences in percentage estimates above.
These trends were statistically significant even after a Bonferroni correction (Since we tested a total of 14 hypotheses for the overall trends with a desired α = 0.05, the Bonferroni correction would test each individual hypothesis at α = 0.05/14 = 0.0036).